Umazume, Akihiko
Ohguro, Nobuyuki
Okada, Annabelle A.
Namba, Kenichi
Sonoda, Koh-Hei
Tsuruga, Hidekazu
Morita, Kazuo
Goto, Hiroshi
Funding for this research was provided by:
AbbVie GK (AbbVie GK)
Article History
Received: 20 October 2021
Accepted: 25 March 2022
First Online: 7 June 2022
Conflicts of interest
: A. Umazume, None; N. Ohguro, None; A. A. Okada, Grants (Bayer, Novartis, Santen, Mitsubishi Tanabe, Alcon, Kowa), Consulting fees (Bayer, AbbVie, Astellas, Biocon Biologics, Daiichi Sankyo, Allergan, Chugai, Novartis), Speaker fees (Bayer, Kowa, Novartis, Santen, Mitsubishi Tanabe, Senju, Alcon, Otsuka, Allergan); K. Namba, Grant (AbbVie, Mitsubishi Tanabe, Eisai, EP-CRSU), Speaker fees (Alcon, Pfizer, Novartis, Kowa, Senju, Mitsubishi Tanabe, Eisai, AbbVie, Santen, Celgene); K. Sonoda, None; H. Goto, None; H. Tsuruga and K. Morita are employees of AbbVie GK and may receive stocks.